Peptide Side Effects by Compound: The 'Peptide Uglies', Red Flags, When to Stop

Key takeaways

There is no single list of peptide side effects. Each compound has its own, and the evidence runs from FDA labels with placebo-controlled rates (tesamorelin, PT-141, semaglutide, tirzepatide, elamipretide) to almost nothing in humans (BPC-157, TB-500, KPV, MOTS-c, injected GHK-Cu).
Growth hormone secretagogues share one profile: fluid retention, joint pain, tingling hands, carpal tunnel and higher blood sugar (on the tesamorelin label, edema 6% versus 2% and new diabetes 5% versus 1%). Melanocortin agonists share another: on the PT-141 label, nausea 40% versus 1%, flushing 20%, a blood pressure rise after every dose and patches of darker skin.
'Peptide uglies' is forum slang, not a medical term, for early reactions such as water retention, a puffy face, lethargy, headache and tingling fingers. No study has measured it, and some of what gets called the uglies is a warning sign rather than an adjustment period.
Many of the worst documented harms came from the product, not the peptide: endotoxin in compounded glutathione made from supplement-grade powder (about 30 patients in 2026), and peptide vials bought from illegal online sellers that tested at 5 to 75 percent purity, with arsenic, or with endotoxin in every sample.
Stop and get care the same day for fever or chills within hours of an injection, spreading redness or pus, hives or facial swelling, severe abdominal pain, chest pain, fainting or a sudden change in vision; call emergency services if breathing is affected.

Peptide side effects depend on which peptide, from which source, injected how. This page compiles the safety sections of our compound profiles into one reference: a master table by class, the class effects, the 'peptide uglies', risks from the vial rather than the molecule, injection problems, red flags and monitoring. Two compounds have their own pages, BPC-157 side effects and sermorelin side effects, and GLP-1 drugs have the GLP-1 side effects guide.

Three sources of harm

The molecule. What the peptide does at the dose you take: nausea from a melanocortin agonist, fluid retention from a growth hormone secretagogue. For approved drugs these effects are measured against placebo and printed on the label.
The product. What else is in the vial, and whether the peptide is there at the stated amount: endotoxin, bacteria, heavy metals, impurities, a different peptide, the wrong dose.
The injection. Site reactions, lumps from injecting the same spot, infection, and errors in drawing up the dose.

For a labeled drug from a pharmacy, most of what you need is the first kind, on the label. For a research peptide all three are open, and the first is often unanswerable because no human has been studied.

Peptide side effects by compound

Rates are drug versus placebo from the FDA label or pivotal trial; where no source gives a rate, the table says so. Read the last column first: 'FDA label' means side effects counted against placebo in hundreds or thousands of people, and 'none' does not mean safe, only that nobody has looked.

Compound	Common side effects (vs placebo where known)	Serious risks	Who should not use it	Safety evidence
Growth hormone secretagogues
Sermorelin	Injection-site pain, swelling or redness in about 1 in 6; headache, flushing, dizziness, hives each under 1%	GH and IGF-1 class effects; anti-GHRH antibodies common in children; hypothyroidism 6.5%	Active or recent cancer; pregnancy; untreated hypothyroidism; uncontrolled diabetes	Former pediatric label; small adult trials
Tesamorelin	Injection-site reactions 17% vs 6%; joint pain 13% vs 11%; edema 6% vs 2%; muscle pain 6% vs 2%; tingling 5% vs 2%; carpal tunnel 1% vs 0%	New diabetes 5% vs 1%; IGF-1 above 2 SD in 47%	Disrupted pituitary axis; active cancer; pregnancy	FDA label; 806-patient trials
CJC-1295 and ipamorelin	No reliable rates; users report water retention, flushing, headache, tingling hands	GH class effects; IGF-1 raised for days (DAC); only disease trial halted after a death, cause unpublished	As for the class	Short hormone studies only
Melanocortin agonists
PT-141	Nausea 40% vs 1%; flushing 20% vs 0.3%; injection-site 13% vs 8%; headache 11% vs 2%; 18% stopped vs 2%	Blood pressure up to 6/3 mmHg after each dose; skin darkening 1%, 38% with daily dosing	Uncontrolled hypertension or cardiovascular disease; pregnancy; oral naltrexone	FDA label; 1,247 women
GLP-1 receptor agonists
Semaglutide 2.4 mg	Nausea 44% vs 16%; diarrhea 30% vs 16%; vomiting 24% vs 6%; constipation 24% vs 11%	Pancreatitis; gallbladder disease; dehydration kidney injury; boxed thyroid tumor warning (rodents)	Medullary thyroid cancer or MEN 2 history; pregnancy	FDA label
Tirzepatide	Nausea 25 to 29% vs 8%; diarrhea 19 to 23% vs 8%; vomiting 8 to 13% vs 2%	Same class risks	Same	FDA label
Mitochondrial and metabolic
SS-31 (elamipretide)	Injection-site reactions 12 of 12 vs 8 of 12	Serious hypersensitivity; eosinophil rise	Prior serious allergy; newborns; severe kidney disease needs half dose	FDA label (Barth syndrome)
MOTS-c	Unknown; analog trial: injection-site reactions only	Unknown; theoretical immune reactions, low blood sugar	Pregnancy; cancer; glucose-lowering drugs	No human trial
NAD+ (not a peptide)	Fast infusions: nausea, cramping, flushing, racing heart, chest pressure	Endotoxin from food-grade powder	Active cancer; Parkinson's disease; unstable heart disease	Pilot studies only
Healing and anti-inflammatory research peptides
BPC-157	No systematic human data; two pilots reported none, a third did not report	Theoretical: tumor blood supply, blood pressure, immune reactions	Cancer history; pregnancy; heart disease; tested athletes	Animal toxicology; 3 uncontrolled pilots
TB-500	None recorded; users describe headache, lethargy, flushing	Parent protein enlarged tumors in mice; contents vary by vendor	Cancer history; pregnancy; anticoagulants; athletes	None for the fragment
KPV	None recorded	Immune suppression; allergy	Immunosuppression; mast-cell disorders; pregnancy	None in humans
Reproductive hormone
Kisspeptin-10	No serious events in short laboratory studies	Frequent dosing shuts the axis down; plaque growth in susceptible mice	Pregnancy or fertility treatment; hormone-sensitive cancer; adolescents	Short laboratory studies
Skin, copper and antioxidant
GHK-Cu	Topical: stinging, copper allergy; injected: unknown	Injected: copper load on the liver, immune reactions	Wilson disease; liver disease; copper allergy	Small topical studies only
Glutathione	Few in short trials	Endotoxin clusters 2018, 2019, 2026; skin and kidney reactions with IV whitening	Asthma or sulfite sensitivity; pregnancy; chemotherapy	Short trials only

Sources: the tesamorelin, PT-141, elamipretide, semaglutide and tirzepatide rows are from their labels (Egrifta WR label 2025) (Vyleesi label) (Forzinity label) (Wegovy label) (Zepbound label); sermorelin from its former label, based on children with growth hormone deficiency (sermorelin label); the BPC-157 animal record from toxicology in four species (Xu 2020). Other rows summarize the linked profiles, where each claim is sourced.

The class effects, explained

Growth hormone secretagogues: fluid, joints, nerves, glucose and IGF-1

Sermorelin, tesamorelin, CJC-1295 and ipamorelin all make the pituitary release more growth hormone, which raises IGF-1, so their side effects follow growth hormone's. The best quantified picture is a systematic review of growth hormone itself in healthy older adults: people given it were significantly more likely to have soft-tissue edema, joint pain, carpal tunnel syndrome and breast enlargement in men, and somewhat more likely to develop diabetes or impaired fasting glucose (Liu 2007). Secretagogues keep the pituitary's feedback loops intact, which should make these effects less likely at physiologic doses. A review of secretagogue trials found them generally well tolerated, with a recurring concern about blood glucose from reduced insulin sensitivity, and noted that cancer incidence and mortality with long-term use have never been evaluated (Sigalos 2018).

The one secretagogue with a current label shows the pattern in numbers: edema, muscle pain and tingling about three times as common as on placebo, carpal tunnel in 1%, and new diabetes in 5% versus 1% over 26 weeks. IGF-1 was more than two standard deviations above normal in 47% of treated patients; the label says to monitor it, to consider stopping when it stays above three, and that the effects of prolonged IGF-1 elevation are unknown. Active cancer is a contraindication because GH and IGF-1 are growth signals (Egrifta WR label 2025).

The practical point: the 'water' effects (puffy hands and ankles, stiff joints, tingling fingers) are felt, while rising glucose usually is not, which is why it has to be measured.

Melanocortin agonists: nausea, flushing, blood pressure, pigment

PT-141 (bremelanotide) acts on melanocortin receptors in the brain and the skin. Nausea affected 40% of women in the phase 3 trials, mostly after the first dose, and 8% quit because of it. Each dose raised blood pressure by up to 6/3 mmHg, peaking two to four hours after injection, and slowed the heart by up to 5 beats a minute, usually back to baseline within 12 hours. Focal hyperpigmentation of the face, gums or breasts occurred in 1% of women using up to eight doses a month and in 38% of those dosed daily for eight days; it was more common in darker skin and did not always resolve after stopping (Vyleesi label).

Melanotan II, the illegal tanning injection, is a close relative with no label at all. The PT-141 profile explains why anyone with a melanoma history or many atypical moles should ask a dermatologist before using any melanocortin agonist.

GLP-1 receptor agonists: the gut first, then a short list of serious risks

Semaglutide and tirzepatide are the most studied peptides on this page. Their side effects are mainly gastrointestinal, dose-related and front-loaded: nausea affected 44% on semaglutide 2.4 mg versus 16% on placebo (Wegovy label) and 25 to 29% on tirzepatide versus 8% (Zepbound label), concentrated in the weeks after each dose increase. The serious risks (pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar with insulin or sulfonylureas, aspiration under anesthesia) and the management of each symptom are in the GLP-1 side effects guide. One risk belongs to compounded vials specifically: FDA has reported patients injecting 5 to 20 times the intended dose after confusing milligrams with syringe units.

What the 'peptide uglies' are

'Peptide uglies' is a phrase from bodybuilding and biohacking forums, not a medical term. People use it loosely for unpleasant reactions in the first days or weeks of a new peptide, most often a growth hormone secretagogue: water retention, a puffy face or hands, lethargy, headache, flushing, tingling fingers, joint aches and lumps at the injection site. It has no fixed definition, no one has counted how often it happens, and a PubMed search in October 2026 returned no paper that uses the term.

Forum advice tends to treat the uglies as a phase to push through. Some of the symptoms match labeled, usually mild class effects; others overlap with problems that are not an adjustment period at all. The table pairs each with its documented counterpart and with the version that should not be waited out.

What gets called the uglies	Documented counterpart	When it is not the uglies
Water retention; puffy face, hands or ankles	Peripheral edema 6% vs 2% on tesamorelin; soft-tissue edema with growth hormone	Swelling of the lips, tongue or throat, or hives (allergic reaction); swelling with breathlessness
Tingling or numb fingers	Paresthesia 5% vs 2% and carpal tunnel 1% vs 0% on tesamorelin	Numbness or weakness that persists, spreads or affects one side of the body
Lethargy and tiredness	Fatigue 11% vs 5% on semaglutide	Tiredness with thirst and frequent urination (possible high blood sugar)
Flushing and headache	Flushing 20% and headache 11% on PT-141	Severe headache, chest pain or fainting
Nausea	40% on PT-141; 44% on semaglutide	Vomiting that stops you keeping fluids down; severe abdominal pain
Joint aches	Joint pain 13% vs 11% on tesamorelin	A single hot, swollen joint, or joint pain with fever
Fever, chills and body aches within hours of a shot	Not a common labeled effect of these peptides	The pattern of the endotoxin clusters below; same-day care

The middle column gives label rates for specific drugs, not rates for the uglies, which have none (Egrifta WR label 2025) (Vyleesi label) (Wegovy label). With a research vial, a reaction cannot even be pinned on the peptide, because nobody knows what else is in it.

Risks that come from the product, not the peptide

Endotoxin

Endotoxin is a residue of bacterial cell walls that survives sterilization. Injected, it causes fever, chills, headache, vomiting and low blood pressure within hours, and shock at high doses. In Sydney, seven people had probable endotoxin poisoning from contaminated compounded glutathione infusions, five of them using it for Lyme disease (Johnstone 2018). In the United States, FDA warned compounders in 2019 after seven patients reacted to one lot, and again on August 27, 2026, after about 30 patients developed fever, chills, dizziness, pain and sepsis-like symptoms, some needing hospital care, from IV glutathione compounded with dietary-supplement-grade powder; two Texas pharmacies recalled products (Pharma Now 2026). In 2024 FDA reported the same pattern with injectable NAD+ made from food-grade material (FDA 2024). The glutathione and NAD+ profiles have the full record. Those products came from licensed pharmacies using the wrong grade of ingredient; a research vial has less oversight, not more.

Wrong purity, wrong amount, wrong ingredients

The best published evidence on what unregulated online peptides contain comes from laboratories that bought and tested them; research vials come from the same kind of supply chain. A Belgian public-health laboratory analyzed the ten falsified peptide drugs it encountered most often from suspected illegal online pharmacies: the amount per vial varied widely, purity ranged from 5 to 75 percent for cysteine-containing peptides, several samples carried arsenic at up to ten times the limit for injectable drugs, and one carried lead (Janvier 2018). A 2024 test purchase of semaglutide vials from illegal online pharmacies found purity of 7.7 to 14.4 percent against the 99 percent on the label, 29 to 39 percent more drug than stated, and endotoxin in all three vials (Ashraf 2024).

Identity is the third problem. When FDA's reviewers assessed BPC-157, TB-500, KPV, MOTS-c and three other peptides in July 2026, they cited uncertain identity and composition, inadequate characterization and immunogenicity, the risk that the immune system reacts to a foreign peptide or its impurities (Kelley Drye 2026).

Dose errors and what a pharmacy fixes

Peptides are measured in micrograms or milligrams and drawn in syringe units, and the conversion is where people get hurt. A labeled vial with a stated concentration, the units guide and the reconstitution calculator remove most of that risk; a research vial of unknown content removes none of it. A licensed 503A pharmacy adds a named source, a beyond-use date and someone accountable, which is why our legal tracker matters for safety and not just for law. It does not guarantee quality, as the glutathione recalls show: ask which pharmacy made the vial, what grade of ingredient it used, and the lot number.

The injection guide covers technique; these are the problems it is designed to prevent.

Site reactions. Redness, itching or a small bump or bruise that fades within a day or two is normal. Rates vary widely: 13% versus 8% on PT-141, 17% versus 6% on tesamorelin, every patient on elamipretide.
Lumps from injecting the same spot. Lipohypertrophy, a rubbery thickening of fat, was present in nearly two-thirds of 430 insulin users in one survey and was linked to not rotating sites and reusing needles. Drug injected into a lump is absorbed unpredictably.
Infection. Spreading redness, warmth, growing swelling, pus or fever; more likely with reused needles, shared vials and non-sterile products.
Allergic reactions. Hives, facial swelling or wheezing; elamipretide's label warns that serious reactions can appear from minutes to months after starting (Forzinity label).

Red flags: stop and seek care

Symptom	What it may be	What to do
Trouble breathing; swelling of the face, lips, tongue or throat	Severe allergic reaction	Call emergency services
Chest pain, fainting or a racing heart that does not settle	Cardiovascular reaction; infusion reaction	Emergency care
Severe abdominal pain, especially spreading to the back	Pancreatitis (GLP-1 drugs) or another emergency	Emergency care
Sudden loss of vision in one eye	Optic nerve stroke, a rare signal with GLP-1 drugs	Emergency care
Confusion, shaking or sweating in someone on insulin or a sulfonylurea	Low blood sugar	Treat it and get help
Fever, chills or rigors within hours of an injection	Endotoxin or infection	Stop the product, keep the vial, same-day care
Spreading redness, warmth or pus at the site	Injection-site infection	Same-day care
Vomiting that stops you keeping fluids down, or very little urine	Dehydration and kidney injury	Same-day care
Numbness or weakness that persists or spreads	Nerve compression or a neurological problem	Same-day call; do not wait for it to pass
New patches of dark skin, or a changing mole	Melanocortin effect, or a skin lesion needing review	See a clinician; the PT-141 label says to consider stopping

If a product was dispensed by a pharmacy, report the reaction to the prescriber and to FDA's MedWatch program (1-800-FDA-1088); the lot number lets a recall reach other patients.

When to stop, and what to monitor

Labeled stop rules. PT-141: stop after eight weeks if desire has not improved, and do not exceed eight doses a month (Vyleesi label). Tesamorelin: consider stopping if IGF-1 stays above three standard deviations or visceral fat does not fall; stop at any sign of cancer recurrence (Egrifta WR label 2025). Sermorelin has no adult label; the sermorelin profile suggests a second look if IGF-1 has not moved after 8 to 12 weeks.

Stop immediately for any red flag above, a new cancer diagnosis, or a pregnancy.

Talk to the prescriber before stopping for anything less urgent; a GLP-1 restarted after two or more missed weekly doses, for example, needs a lower starting dose.

Class	What to check	When
GH secretagogues (sermorelin, tesamorelin)	IGF-1; fasting glucose or HbA1c; basic metabolic panel	Before starting, at 8 to 12 weeks, then every 3 to 6 months
Sermorelin specifically	Thyroid function (the former label asked for it before and during treatment)	Before starting and during treatment
PT-141	Blood pressure	Before the first prescription and periodically
GLP-1 drugs	Kidney function if vomiting or diarrhea; glucose with insulin or sulfonylureas; eyes if there is diabetic retinopathy	As symptoms or history require
Elamipretide	Kidney function (dose depends on it)	Before starting
Research peptides	No validated monitoring exists, because no one has defined what to look for	Not applicable

A program that sells a GH secretagogue without ever measuring IGF-1 and glucose is not monitoring anything.

Bottom line

'Peptide side effects' covers drugs with thousands of trial participants and research chemicals with none. For the labeled peptides the side effects are known, mostly mild and listed with numbers: nausea and blood pressure with PT-141; fluid, joints and glucose with growth hormone secretagogues; the gut with GLP-1 drugs. For the research peptides the honest entry is 'unknown', and the documented harms of that market come from the vial: endotoxin, impurities and wrong doses.

The 'peptide uglies' are a forum name for real symptoms, some of them labeled class effects and some of them warnings. Know the red flags, keep the vial and the lot number, and use a product from a pharmacy that can tell you what is in it.

Frequently asked questions

+What are the peptide uglies?

'Peptide uglies' is forum slang, not a medical term, for the unpleasant reactions some people describe in the first days or weeks of a new peptide: water retention, a puffy face or hands, lethargy, headache, flushing, tingling fingers and injection-site lumps. It is used most often about growth hormone secretagogues such as CJC-1295, ipamorelin and sermorelin. No study has measured it, so there is no incidence figure. Several of the symptoms match labeled class effects (edema and tingling on the tesamorelin label, flushing and nausea on the PT-141 label), but others, such as fever and chills after a shot or swelling of the lips, are warning signs and not something to push through.

+How long do the peptide uglies last?

Nobody knows, because the term has never been studied. For the labeled drugs there is some timing data: GLP-1 nausea episodes lasted a median of 8 days in the semaglutide trials and clustered after dose increases, and PT-141 nausea was most common after the first dose. For growth hormone secretagogues there is no comparable timing data. Anything that is getting worse rather than better, or that matches a red flag on this page, should be reported to a clinician rather than waited out.

+Are peptides 100% safe?

No drug is, and peptides range from well characterized to completely unknown. FDA-approved peptides such as tesamorelin, bremelanotide, semaglutide and tirzepatide have labels with measured side-effect rates and contraindications. Research peptides such as BPC-157, TB-500, KPV and MOTS-c have little or no human safety data, and the vials they come in have no verified content or sterility. 'Natural' or 'made by the body' does not mean safe at injected doses.

+What are the negative side effects of peptide injections?

The injection itself can cause redness, itching, bruising, lumps of thickened fat from injecting the same spot, infection and allergic reactions. The product can add endotoxin, which causes fever, chills and low blood pressure within hours, and wrong doses from mislabeled vials. Then come the effects of the specific peptide: nausea and blood pressure changes with PT-141, fluid retention and higher blood sugar with growth hormone secretagogues, gastrointestinal effects with GLP-1 drugs, and unknowns with research peptides.

+What are the long-term side effects of peptides?

For most peptides sold online, unknown: no one has followed users for years. The longest data come from approved drugs, such as about three years of semaglutide in a cardiovascular trial and up to 168 weeks of elamipretide in eight men with Barth syndrome. For growth hormone secretagogues, a 2018 review noted that cancer incidence and mortality with long-term use have never been evaluated, and the tesamorelin label says the effects of prolonged IGF-1 elevation are not known.

+What is the safest peptide to take?

There is no peptide that is safe for everyone, and this page does not recommend one. The peptides whose risks are best characterized are the FDA-approved ones, because their labels list measured side-effect rates, contraindications and monitoring. Whether one of them is reasonable for you depends on your history and should be decided with a clinician who will check the labs the label calls for. Research peptides are the least characterized, whatever their reputation.

+Are peptides bad for your heart?

Some carry specific cardiovascular cautions. PT-141 raises blood pressure by up to about 6 mmHg after each dose and is contraindicated in uncontrolled hypertension or known cardiovascular disease. Growth hormone secretagogues can raise blood sugar, and the tesamorelin label says long-term cardiovascular safety has not been established. Fast NAD+ infusions cause a racing heart and chest pressure. BPC-157's heart claims come from rat studies only. Anyone with heart disease should treat every unapproved peptide as an unknown.

+When should I stop taking a peptide?

Stop and seek care the same day for fever or chills within hours of an injection, spreading redness or pus at the site, hives or swelling of the face, severe abdominal pain, chest pain, fainting or a sudden change in vision; call emergency services if breathing is affected. For prescribed peptides, follow the label's stop rules (PT-141 after 8 weeks without benefit; tesamorelin if IGF-1 stays very high or visceral fat does not fall) and talk to the prescriber before stopping for anything less urgent.